1889-77-6

Basic information

• Product Name: Ethanone, 2-bromo-1-(4-methoxyphenyl)-2-phenyl-
• CAS NO: 1889-77-6
• Molecular Formula: C15H13BrO2
• Molecular Weight: 305.171
• Mol File: 1889-77-6.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Ethanone, 2-bromo-1-(4-methoxyphenyl)-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-(4-methoxyphenyl)-2-phenyl-(1889-77-6)
• EPA Substance Registry System: Ethanone, 2-bromo-1-(4-methoxyphenyl)-2-phenyl-(1889-77-6)

Safety Data

• Hazardous Substances Data: 1889-77-6(Hazardous Substances Data)

Usage

General Description

Ethanone, 2-bromo-1-(4-methoxyphenyl)-2-phenyl- is a chemical compound with the molecular formula C16H13BrO2. It is also known by the trade name Brivaracetam and is commonly used as an antiepileptic drug. The compound has been studied for its potential in treating various types of seizures and is believed to work by modulating synaptic vesicle protein 2A (SV2A), which plays a role in regulating neurotransmitter release. Its structure consists of a bromine atom attached to a phenyl ring, which is in turn connected to a methoxyphenyl group and a ketone functional group. It is important to handle this compound with care and follow appropriate safety protocols when working with it in a laboratory setting.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 103-80-0 phenylacetyl chloride 
• 100-66-3 methoxybenzene 
• 32320-41-5 2-(4-methoxyphenyl)-1-nitro-1-phenylethylene 
• 1023-17-2 4-methoxyphenyl benzyl ketone 

Downstream Products

• 108791-38-4 2-acetoxy-1-(4-methoxyphenyl)-2-phenylethanone 
• 5834-42-4 3-(4-methoxyphenyl)-2-phenyl-1H-indole 
• 1240167-90-1 C₂₂H₁₅N₃O₃S 
• 855404-92-1 4-(4-methoxyphenyl)-2-methyl-5-phenyloxazole 
• 1889-74-3 1-(4-methoxyphenyl)-2,2-diphenylethanone 
• 4873-38-5 4'-hydroxy-2,2-diphenylacetophenone 
• 97295-17-5 2-(4-methoxyphenyl)-3-phenylglycidonitrile 
• 4578-79-4 2-(4-methoxyphenyl)-2-phenylacetonitrile 
• 16762-14-4 α-(3-Methoxyphenoxy)-4-methoxydesoxybenzoin 
• 1455272-60-2 4-(4-methoxyphenyl)-5-(phenyl)-2-(benzylthio)-thiazole 
• 1455272-58-8 4-(4-methoxyphenyl)-5-(phenyl)-2-(methylthio)-thiazole 
• 1446909-41-6 4-(4-methoxyphenyl)-1-methyl-2-(methylthio)-5-phenyl-1H-imidazole 
• 1446909-35-8 4-(4-methoxyphenyl)-1-methyl-5-phenyl-1H-imidazole-2(3H)-thione 
• 1403893-90-2 C₂₈H₃₂N₄O₂S 

Relevant articles and documents

Reactivity of substrates with multiple competitive reactive sites toward NBS under neat reaction conditions promoted by visible light

Regioselectivity of visible-light-induced transformations of a range of (hetero)aryl alkyl-substituted ketones bearing several competitive reactive sites (α-carbonyl, benzyl and aromatic ring) with N-bromosuccinimide (NBS) was studied under solvent-free reaction conditions (SFRC) and in the absence of inert-gas atmosphere, radical initiators and catalysts. An 8-W energy-saving household lamp was used for irradiation. Heterogeneous reaction conditions were dealt with throughout the study. All substrates were mono- or dibrominated at the α-carbonyl position, and additionally, some benzylic or aromatic bromination was observed in substrates with benzylic carbon atoms or electron-donating methoxy groups, respectively. Surprisingly, ipso-substitution of the acyl group with a bromine atom took place with (4-methoxynaphthyl) alkyl ketones. While the addition of the radical scavenger TEMPO (2,2,6,6-tetramethylpiperidin-1-yloxy) decreased the extent of α- and ring bromination, it completely suppressed the benzylic bromination and α,α-dibromination with NBS under SFRC.

Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain

The emerging pharmacological target soluble epoxide hydrolase (sEH) is a bifunctional enzyme exhibiting two different catalytic activities that are located in two distinct domains. Although the physiological role of the C-terminal hydrolase domain is well-investigated, little is known about its phosphatase activity, located in the N-terminal phosphatase domain of sEH (sEH-P). Herein we report the discovery and optimization of the first inhibitor of human and rat sEH-P that is applicable in vivo. X-ray structure analysis of the sEH phosphatase domain complexed with an inhibitor provides insights in the molecular basis of small-molecule sEH-P inhibition and helps to rationalize the structure-activity relationships. 4-(4-(3,4-Dichlorophenyl)-5-phenyloxazol-2-yl)butanoic acid (22b, SWE101) has an excellent pharmacokinetic and pharmacodynamic profile in rats and enables the investigation of the physiological and pathophysiological role of sEH-P in vivo.

Thiazole Compounds and Uses Thereof

The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.